Advaxis Stumbles Further As Amgen Exits EarlyStage Cancer Immunotherapy Pact

Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact

11:38 EST 14 Dec 2018 | SCRIP

Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase...